ERIS Lifesciences delivered exceptional financial performance in Q3 FY2026, with consolidated net profit surging 172.69% year-on-year to ₹279.10 crore compared to ₹108.83 crore in the corresponding quarter of the previous year. According to the latest unaudited financial results approved by the Board of Directors on July 29, 2026, this remarkable profit growth demonstrates the company's strong operational efficiency and market positioning during the quarter. The effective tax rate improved to 20% from 22.5% in the previous year, contributing significantly to the bottom-line growth. Net profit also showed a quarter-on-quarter increase of 156.46% from the previous quarter, indicating sustained momentum in profitability.
The company's consolidated revenue from operations increased 7.27% year-on-year to ₹756.56 crore in Q3 FY2026, though it declined 6.30% quarter-on-quarter from ₹807.45 crore in Q2 FY2026. As reported in the latest financial results, this revenue growth was primarily driven by the Domestic Branded Formulations (DBF) segment, which recorded organic revenue growth of 14.2%. The Insulin segment grew by 27.7% to ₹412 crore, driven by market share gains in Rapid-Acting Human Insulin (RHI) and Glargine, where Eris' share increased from 9% to 16% since the Biocon acquisition. The GLP-1 segment surged by 165.5%, with the brand Sundae securing the #1 rank in prescriptions (21% share) and units (20% share) in the generic semaglutide market.
Operating profit demonstrated strong sequential growth, increasing 3.03% quarter-on-quarter to ₹272.37 crore from ₹264.37 crore in Q2 FY2026, while showing robust 7.92% year-on-year growth. PBDT (Profit Before Depreciation and Tax) grew 6.16% QoQ to ₹228.98 crore from ₹215.69 crore, reflecting improved operational efficiency. Profit Before Tax surged 9.67% QoQ to ₹159.41 crore from ₹145.35 crore, indicating enhanced bottom-line performance across all profitability metrics. This sequential improvement suggests the company's operational challenges from earlier quarters are being effectively addressed through improved cost management and operational efficiency.
Despite margin pressures, operating cash flow remained robust at 77% of EBITDA, demonstrating strong cash conversion capabilities. The company's promoter holding remained stable at 54.14% as of June 2026, with Domestic Institutional Investors (DIIs) holding 20.71% and Foreign Portfolio Investors (FPIs) at 14.39%. Management outlined key priorities for the next two quarters, including driving the Oral Anti-Diabetics (OAD) segment to 70% of market growth, commercializing Eris Bionxt for supply control, and entering the non-represented Insulin Analogs market valued at ₹2,309 crore. Seven out of ten therapy categories in the portfolio recorded double-digit growth, with the Insulin segment benefiting from market share gains across key products.
